KD Logo

United Therapeutics Corp (UTHR) receives a Neutral rating from Goldman

United Therapeutics Corp’s recent filing unveils that its CHAIRPERSON & CEO ROTHBLATT MARTINE A unloaded Company’s shares for reported $0.96 million on May 13 ’24. In the deal valued at $265.48 per share,3,600 shares were sold. As a result of this transaction, ROTHBLATT MARTINE A now holds 130 shares worth roughly $35071.399999999994.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, ROTHBLATT MARTINE A sold 3,600 shares, generating $955,788 in total proceeds. Upon selling the shares at $265.50, the CHAIRPERSON & CEO now owns 130 shares.

Before that, ROTHBLATT MARTINE A sold 3,600 shares. United Therapeutics Corp shares valued at $951,206 were divested by the CHAIRPERSON & CEO at a price of $264.22 per share. As a result of the transaction, ROTHBLATT MARTINE A now holds 130 shares, worth roughly $35071.399999999994.

Goldman upgraded its United Therapeutics Corp [UTHR] rating to a Neutral from a a Sell in a research note published on February 12, 2024; the price target was increased to $215 from $213. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Wells Fargo began covering UTHR with “an Overweight” recommendation on December 08, 2023. UBS started covering the stock on December 06, 2022. It rated UTHR as “a Buy”.

Price Performance Review of UTHR

On Tuesday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock jump 2.06% to $269.78. Over the last five days, the stock has gained 1.34%. United Therapeutics Corp shares have risen nearly 22.69% since the year began. Nevertheless, the stocks have risen 26.05% over the past one year. While a 52-week high of $269.81 was reached on 05/14/24, a 52-week low of $204.44 was recorded on 02/08/24. SMA at 50 days reached $242.03, while 200 days put it at $230.77. A total of 0.39 million shares were traded, compared to the trading of 0.35 million shares in the previous session.

Levels Of Support And Resistance For UTHR Stock

The 24-hour chart illustrates a support level at 266.14, which if violated will result in even more drops to 262.51. On the upside, there is a resistance level at 271.62. A further resistance level may holdings at 273.47. The Relative Strength Index (RSI) on the 14-day chart is 70.24, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 11.11, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 0.14%. Stochastics %K at 89.91% indicates the stock is a selling.

The most recent change occurred on December 05, 2022 when Goldman began covering the stock and recommended ‘”a Sell”‘ rating along with a $230 price target.

Most Popular